HighTower Advisors LLC increased its position in shares of Takeda Pharmaceutical Company Limited (NYSE:TAK - Free Report) by 199.5% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 122,587 shares of the company's stock after purchasing an additional 81,653 shares during the quarter. HighTower Advisors LLC's holdings in Takeda Pharmaceutical were worth $1,744,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds have also recently modified their holdings of the company. Catalytic Wealth RIA LLC lifted its holdings in shares of Takeda Pharmaceutical by 4.0% during the second quarter. Catalytic Wealth RIA LLC now owns 21,703 shares of the company's stock worth $281,000 after purchasing an additional 841 shares during the period. EverSource Wealth Advisors LLC raised its position in Takeda Pharmaceutical by 38.6% during the second quarter. EverSource Wealth Advisors LLC now owns 3,082 shares of the company's stock valued at $43,000 after acquiring an additional 859 shares in the last quarter. Hexagon Capital Partners LLC raised its position in Takeda Pharmaceutical by 34.3% during the third quarter. Hexagon Capital Partners LLC now owns 4,419 shares of the company's stock valued at $63,000 after acquiring an additional 1,129 shares in the last quarter. Gallacher Capital Management LLC raised its position in Takeda Pharmaceutical by 7.0% during the second quarter. Gallacher Capital Management LLC now owns 17,365 shares of the company's stock valued at $225,000 after acquiring an additional 1,136 shares in the last quarter. Finally, Cutter & CO Brokerage Inc. raised its position in Takeda Pharmaceutical by 3.3% during the second quarter. Cutter & CO Brokerage Inc. now owns 41,974 shares of the company's stock valued at $543,000 after acquiring an additional 1,347 shares in the last quarter. Institutional investors and hedge funds own 9.17% of the company's stock.
Takeda Pharmaceutical Stock Performance
TAK stock traded down $0.03 during trading on Friday, hitting $13.42. 1,096,799 shares of the company traded hands, compared to its average volume of 1,875,097. The stock's 50-day simple moving average is $13.81 and its 200 day simple moving average is $13.88. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.28 and a quick ratio of 0.77. The company has a market cap of $42.70 billion, a PE ratio of 23.14, a P/E/G ratio of 0.25 and a beta of 0.51. Takeda Pharmaceutical Company Limited has a 1 year low of $12.57 and a 1 year high of $15.08.
Takeda Pharmaceutical Profile
(
Free Report)
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.
Read More
Before you consider Takeda Pharmaceutical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Takeda Pharmaceutical wasn't on the list.
While Takeda Pharmaceutical currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link below to learn more about using beta to protect yourself.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
